NYSE - Delayed Quote USD

DaVita Inc. (DVA)

Compare
141.59 +1.78 (+1.27%)
At close: November 1 at 4:00 PM EDT
141.03 -0.56 (-0.40%)
After hours: November 1 at 7:44 PM EDT
Loading Chart for DVA
DELL
  • Previous Close 139.81
  • Open 141.64
  • Bid 141.03 x 800
  • Ask 141.76 x 800
  • Day's Range 140.51 - 143.42
  • 52 Week Range 78.05 - 168.50
  • Volume 659,524
  • Avg. Volume 790,856
  • Market Cap (intraday) 11.614B
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) 15.27
  • EPS (TTM) 9.27
  • Earnings Date Oct 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 160.39

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

www.davita.com

70,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DVA

View More

Performance Overview: DVA

Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DVA
35.16%
S&P 500
20.10%

1-Year Return

DVA
83.34%
S&P 500
36.60%

3-Year Return

DVA
37.15%
S&P 500
24.39%

5-Year Return

DVA
141.62%
S&P 500
88.60%

Compare To: DVA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DVA

View More

Valuation Measures

Annual
As of 11/1/2024
  • Market Cap

    11.61B

  • Enterprise Value

    22.72B

  • Trailing P/E

    15.26

  • Forward P/E

    12.38

  • PEG Ratio (5yr expected)

    1.07

  • Price/Sales (ttm)

    1.00

  • Price/Book (mrq)

    30.03

  • Enterprise Value/Revenue

    1.79

  • Enterprise Value/EBITDA

    8.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.53%

  • Return on Assets (ttm)

    6.94%

  • Return on Equity (ttm)

    44.88%

  • Revenue (ttm)

    12.67B

  • Net Income Avi to Common (ttm)

    827.68M

  • Diluted EPS (ttm)

    9.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.09B

  • Total Debt/Equity (mrq)

    549.55%

  • Levered Free Cash Flow (ttm)

    1.11B

Research Analysis: DVA

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 3.26B
Earnings 214.69M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

137.12
160.39 Average
141.59 Current
186.00 High
 

Company Insights: DVA

Research Reports: DVA

View More
  • DaVita Earnings: New Debt Costs Pressure 3Q Results, but 2024 Outlook Remains Intact

    DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

    Rating
    Price Target
     
  • DaVita Earnings: New Debt Costs Pressure 3Q Results, but 2024 Outlook Remains Intact

    DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

    Rating
    Price Target
     
  • DaVita Earnings: New Debt Costs Pressure 3Q Results, but 2024 Outlook Remains Intact

    DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 250,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of the US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

    Rating
    Price Target
     
  • Lowering target price to $166.00

    DAVITA INC has an Investment Rating of HOLD; a target price of $166.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch